MX2018002450A - Formulacion de liberacion extendida, retardada e inmediata, metodo de fabricacion y uso de la misma. - Google Patents

Formulacion de liberacion extendida, retardada e inmediata, metodo de fabricacion y uso de la misma.

Info

Publication number
MX2018002450A
MX2018002450A MX2018002450A MX2018002450A MX2018002450A MX 2018002450 A MX2018002450 A MX 2018002450A MX 2018002450 A MX2018002450 A MX 2018002450A MX 2018002450 A MX2018002450 A MX 2018002450A MX 2018002450 A MX2018002450 A MX 2018002450A
Authority
MX
Mexico
Prior art keywords
extended
delayed
manufacturing
immediate release
release formulation
Prior art date
Application number
MX2018002450A
Other languages
English (en)
Inventor
A Dill David
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/842,509 external-priority patent/US10105330B2/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of MX2018002450A publication Critical patent/MX2018002450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se describen composiciones para reducir la frecuencia de micciones y métodos para fabricar las composiciones. Las composiciones comprenden un primer componente que tiene un subcomponente de liberación inmediata y un subcomponente de liberación extendida, en donde el primer componente se formula para liberar los subcomponentes inmediatamente después de la administración; y un segundo componente que comprende un subcomponente de liberación inmediata y un subcomponente de liberación extendida, en donde el segundo componente se formula para una liberación retardada de los subcomponentes.
MX2018002450A 2015-09-01 2016-07-07 Formulacion de liberacion extendida, retardada e inmediata, metodo de fabricacion y uso de la misma. MX2018002450A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/842,509 US10105330B2 (en) 2012-01-04 2015-09-01 Extended, delayed and immediate release formulation method of manufacturing and use thereof
PCT/US2016/041352 WO2017039832A1 (en) 2015-09-01 2016-07-07 Extended, delayed and immediate release formulation method of manufacturing and use thereof

Publications (1)

Publication Number Publication Date
MX2018002450A true MX2018002450A (es) 2018-08-24

Family

ID=58188714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002450A MX2018002450A (es) 2015-09-01 2016-07-07 Formulacion de liberacion extendida, retardada e inmediata, metodo de fabricacion y uso de la misma.

Country Status (11)

Country Link
US (2) US20170319520A1 (es)
EP (1) EP3344240A4 (es)
JP (1) JP2018526441A (es)
KR (1) KR20180054655A (es)
CN (1) CN108135870A (es)
AU (1) AU2016317092A1 (es)
HK (1) HK1256098A1 (es)
MX (1) MX2018002450A (es)
RU (1) RU2018111400A (es)
SG (1) SG11201805810PA (es)
WO (1) WO2017039832A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US6126967A (en) * 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20100172983A1 (en) * 2001-06-01 2010-07-08 Plachetka John R Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20050136112A1 (en) * 2003-12-19 2005-06-23 Pediamed Pharmaceuticals, Inc. Oral medicament delivery system
CA2578474A1 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
CN101132769A (zh) * 2005-02-10 2008-02-27 奥瑞克索股份公司 用于药物的跨黏膜给药的药物组合物
US20070212417A1 (en) * 2006-03-07 2007-09-13 Cherukuri S R Compressible resilient granules and formulations prepared therefrom
ES2524556T3 (es) * 2006-10-09 2014-12-10 Charleston Laboratories, Inc. Composiciones farmacéuticas
JP5389656B2 (ja) * 2006-10-20 2014-01-15 マクニール−ピーピーシー・インコーポレーテツド アセトアミノフェン／イブプロフェンの組み合わせおよびこれらの使用方法
US20080026054A1 (en) * 2007-04-27 2008-01-31 Nectid Inc. Novel anelgesic combination
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
RU2010153904A (ru) * 2008-06-02 2012-07-20 Др. Редди'С Лабораторис Лтд. (In) Ниацин-содержащие композиции с модифицированным высвобождением
US20100130617A1 (en) * 2008-11-22 2010-05-27 Auspex Pharmaceuticals, Inc. Ethanolamine modulators of nmda receptor and muscarinic acetylcholine receptor
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
US9415048B2 (en) * 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20150010599A1 (en) * 2010-07-08 2015-01-08 WELLESLEY PHARMACELJTlCALS, LLC Pharmaceutical formulation for reducing bladder spasms and method of use thereof
ES2717178T3 (es) * 2011-03-21 2019-06-19 Broda Tech Co Ltd Composiciones de hidrogel inversamente termorreversible
CA2856677A1 (en) * 2012-01-04 2013-07-11 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
KR20180023057A (ko) * 2012-01-04 2018-03-06 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
CN103191430A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的缓释制剂及其使用方法
WO2013175500A1 (en) * 2012-04-23 2013-11-28 Cadila Healthcare Limited Delazed release pharmaceutical compositions of salsalate
BR112014031306A2 (pt) * 2012-07-27 2017-06-27 A Dill David composição farmacêutica e respectivos usos
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
RU2704613C2 (ru) * 2014-11-11 2019-10-30 Д-Р Редди'С Лабораторис Лимитед Фармацевтические препараты с фиксированной комбинацией доз обезболивающего и антиспазматического агентов

Also Published As

Publication number Publication date
HK1256098A1 (zh) 2019-09-13
WO2017039832A1 (en) 2017-03-09
JP2018526441A (ja) 2018-09-13
CN108135870A (zh) 2018-06-08
EP3344240A1 (en) 2018-07-11
RU2018111400A (ru) 2019-10-03
EP3344240A4 (en) 2019-09-04
US20170319521A1 (en) 2017-11-09
SG11201805810PA (en) 2018-08-30
KR20180054655A (ko) 2018-05-24
US20170319520A1 (en) 2017-11-09
AU2016317092A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
MX2019015744A (es) Composiciones farmaceuticas.
BR112017015580A2 (pt) composição de limpeza para lavagem de louça, e, método para formar uma composição de limpeza para lavagem de louça
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
EA201501024A1 (ru) Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
NZ720813A (en) Composition and method for aiding sleep
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
CL2018001298A1 (es) Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
IL283968A (en) Benzamides of pyrazole-amino-pyrimidine type substances and their use
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
EP3646855A4 (en) COMPOSITION FOR SOLID PREPARATION FOR ORAL USE INCLUDING A PROTON PUMP INHIBITOR, SOLID PREPARATION FOR ORAL USE INCLUDING IT, AND PROCESS FOR PREPARATION
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
MX366651B (es) Forma a cristalina de (r)-2-((3-(3-aminopiperidin-1-il)-6-metil-5- oxo-1,2,4-triazin-4(5h)-il)metil)-4-fluorobenzonitrilo monobenzoato y método de preparación del mismo y composición farmacéutica que comprende la misma.
MX2019003684A (es) Formas cristalinas de un derivado de acido biliar.
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
MX2018002450A (es) Formulacion de liberacion extendida, retardada e inmediata, metodo de fabricacion y uso de la misma.
MX2018014759A (es) Sal farmaceuticamente aceptable como inhibidor del canal de potasio medular externo renal.
MX2015016603A (es) Composiciones de corticosteroides.
EP3081581A4 (en) Diazoresin, photoresist composition and preparation method of photoresist composition
EP3355864A4 (en) COMPOSITION FOR REDUCING THE FREQUENCY OF MICTION, METHOD FOR MANUFACTURING AND USE THEREOF
GR20150100035A (el) Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου
MX2017003878A (es) Formulacion farmaceutica para reducir contracciones de la vejiga y metodo para utilizar la misma.
EP3725804A4 (en) ANTI-BMP10 ANTIBODY AND THERAPEUTIC AGENT FOR HIGH BLOOD PRESSURE AND HIGH PRESSURE DISEASES, CONTAINING THE ANTIBODY AS AN ACTIVE SUBSTANCE